A more recent version of this regulatory record is available. This version is kept only as a historical record. Please see the Record history section for link to the most recent version.
List details
Basic info
| Status | Opinion development |
|---|---|
| Details on the scope of restriction | Manufacturers, importers and downstream users of the substance on its own (regardless of whether DMAC, NEP are a (main) constituent, an impurity or a stabilizer) or in mixtures in a concentration equal or greater than 0.3 % shall use in their chemical safety assessment and safety data sheets by [date to be specified] a worker based harmonized Derived No Effect Level (DNEL) value [to be specified] for long-term inhalation exposure and a worker based harmonized DNEL value [to be specified] for long-term dermal exposure. Manufacturers and downstream users are to implement appropriate risk management measures ensuring exposure of workers remains below the specified DNEL(s). The scope may become wider during the development of the Annex XV in case unacceptable risk is identified for consumers due to DMAC and/or NEP presence in consumer articles (or product formulations below 0.3%). |
| Further substance information | Substances relevant to this restriction proposal: N,N-dimethylacetamide (DMAC) (EC: 204-826-4) and 1-ethylpyrrolidin-2-one (NEP) (EC: 220-250-6). The substances are two polar aprotic solvents. Both of them have been registered under REACH, and have a harmonized CLP classification as Reprotoxic category 1B. |
| Reason for restriction | Widespread industrial and professional uses of DMAC and NEP. There is a high potential for worker exposure as some of the uses are open applications. Based on available information and following existing guidance DNELs should be significantly lower than applied in REACH registration dossiers. The RMOA on polar aprotic solvents concluded restriction as the most appropriate RMO. The proposal is consistent with the approach taken in the existing restriction on NMP and the recent Italian restriction proposal on DMF. |
| CLP Annex VI Index Number |
|
Intention timeline
| Date of intention | 2019-12-09 |
|---|---|
| Expected date of submission | 2022-04-08 |
| Latest update | 2022-06-22 |
Support information
| Restriction report and annexes |
|
|---|
Related substances
No substances related to this record were found in our database.
Related regulatory records
Record history
The following timeline shows when we detected changes of this regulatory record (the date might slightly differ from the date of the actual change). Additions between versions are hightlighted in green color, red color shows data removed between versions.
July 13, 2022
- Latest update: 2022-06-22 → 2022-06-27
This version
June 24, 2022
- Latest update: 2022-05-13 → 2022-06-22
- Restriction report and annexes: https://echa.europa.eu/documents/10162/733cfe8a-f40f-ed4b-72fd-208712fd5f7c → https://echa.europa.eu/documents/10162/a3b07a9a-1144-9507-69a0-ebfed72b1baa
- Restriction report and annexes: https://echa.europa.eu/documents/10162/d59c5e7b-67f4-14ef-beb4-a0218540b67f → https://echa.europa.eu/documents/10162/dff3eb3e-98ce-c1eb-99c9-1812dbb5e54d
- Status: Conformity check → Opinion development
June 6, 2022
- Latest update: 2022-04-19 → 2022-05-13
- Status: Submitted → Conformity check
- Restriction report and annexes: https://echa.europa.eu/documents/10162/733cfe8a-f40f-ed4b-72fd-208712fd5f7c
- Restriction report and annexes: https://echa.europa.eu/documents/10162/d59c5e7b-67f4-14ef-beb4-a0218540b67f